论文部分内容阅读
目的 :探讨食道静脉破裂出血内镜治疗中的血浆降钙素基因相关肽水平变化的机理。方法 :自 1 999年 4月以来 ,在 47例肝硬化食道静脉破裂出血患者中 ,随机选择 2 7例应用硬化剂治疗 ,2 0例使用套扎治疗。应用放射免疫分析法测定 47例患者治疗前后的血浆CGRP水平的变化及临床意义。结果 :硬化剂组血浆CGRP水平治疗前CGRP(87± 2 3)ng/L ,显著高于治疗后 (55± 2 8)ng/L ,P <0 .0 5 ;套扎器组治疗前CGRP(1 0 3± 2 7)显著高于治疗后CGRP(79± 2 0 ) ,P <0 .0 1 ;硬化与套扎二组比较 ,患者的血浆CGRP水平无显著性相关。结论 :在食道静脉破裂出血的内镜治疗中 ,应用硬化剂与套扎是一种有效的方法 ,其机制与影响CGRP基因表达、血流动力学紊乱有关
Objective: To investigate the mechanism of plasma calcitonin gene-related peptide in endoscopic treatment of esophageal variceal bleeding. METHODS: From April 1999 to April 1997, 47 patients with cirrhosis esophageal variceal bleeding were randomized to receive sclerotherapy and 20 patients received ligation. The changes and clinical significance of plasma CGRP levels in 47 patients before and after treatment by radioimmunoassay. Results: The level of plasma CGRP in the sclerotherapy group before treatment was (87 ± 23) ng / L, significantly higher than that after treatment (55 ± 28 ng / L, P <0.05) (103 ± 27) was significantly higher than that of CGRP after treatment (79 ± 20), P <0.01; there was no significant correlation between plasma CGRP levels and sclerosis in both groups. Conclusions: The use of sclerosing agents and ligation in the treatment of esophageal variceal bleeding is an effective method, the mechanism of which is related to the influence of CGRP gene expression and hemodynamic disturbances